Therapeutic niche of Ceftazidime-avibactam

ISBN-13: 9786203827095 / Angielski / Miękka / 88 str.

Natalia Muñoz-Angulo; Daniel Augusto Martin-Arsanios; Diego Alejandro Cubides-Diaz

Opis

Antibiotic resistance is a major public health problem. Gram-negative infections with multi-resistance are responsible for 700,000 deaths per year. It is estimated that by the year 2050 it could reach figures of up to 10 million deaths per year and become the leading cause of mortality above cardiovascular and oncological diseases. This discouraging outlook has prompted research into new antimicrobials, some of which, such as Ceftazidime-avibactam (CAZ-AVI), have already been introduced into clinical practice. Given its high efficacy and low incidence of adverse effects, it has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonias. This is a narrative review of the literature covering the main issues related to this antimicrobial, as well as what has been reported so far in our country.

O autorze

Muñoz-Angulo, Natalia Natalia Muñoz Angulo, graduated from El Bosque University.Daniel Augusto Martin Arsanios, graduated from Universidad de La Sabana, Department of Internal Medicine, Universidad de La Sabana.Diego Alejandro Cubides Diaz, graduated from Universidad el Bosque, Department of Internal Medicine, Universidad de La Sabana.